When COVID-19 vaccines first rolled out, the dominant narrative celebrated scientific triumph. Yet beneath that success lay a more complex legal story. Patents were not the only obstacle, but they became the focal point of a deeper structural tension: how to balance innovation incentives with equitable access. Today, as the global race for climate technologies accelerates, a familiar pattern is emerging.